Verastem Inc (VSTM)

$6.30 +0.05 (0.80%)
Market Cap 407.33M
Revenue (ttm) 10.00M
Net Income (ttm) -130.64M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,306.40%
Debt to Equity Ratio -5.03
Volume 1,036,200
Avg Vol 1,966,678
Day's Range N/A - N/A
Shares Out 66.78M
Stochastic %K 38%
Beta 0.44
Analysts Strong Sell
Price Target $16.00

Company Profile

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 292 4200
Address:
117 Kendrick Street, Suite 500, Needham, United States
CrozrX
CrozrX Feb. 4 at 2:53 AM
$VSTM First case where a tumor would rather get resected, than treated with VS-7375! Just hearing the name! 🤣 Joke aside, not easy situation having this dilemma! I'd say resectable first, then VS-7375/gemcitabine
0 · Reply
Geraldgenofranco1953
Geraldgenofranco1953 Feb. 4 at 1:03 AM
$SLS $IBRX $VSTM I do not know about others but Jack among few of the best traders I follow here in ST! I have been following him for years!
1 · Reply
jacksparo
jacksparo Feb. 4 at 12:26 AM
$SLS $IBRX $VSTM Shorting any cancer treatments stock in my personal opinion! Only my personal! Is really bad to the point I can feel the same disgusting feelings that I get when I heard about some criminal stealing the money that might help any person you love to live longer!!! RED LINE SERIOUS BLOCK!
2 · Reply
OneSmartBull
OneSmartBull Feb. 3 at 11:42 PM
$VSTM looks good
0 · Reply
idkmikes57
idkmikes57 Feb. 3 at 6:57 PM
$VSTM just looking back at this POS I owned still the same old.
0 · Reply
Fadoman
Fadoman Feb. 3 at 2:56 PM
$VSTM now volume has to show up I'm starting to think that only news will make it possible.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 3 at 2:18 PM
$VSTM RSI: 35.86, MACD: -0.5091 Vol: 0.52, MA20: 6.76, MA50: 8.19 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SagehenNed
SagehenNed Feb. 3 at 1:18 PM
$VSTM Check out ANL. Just raised $140 million and is surging pre-market. It now has a market cap greater than VSTM, all off a PR. Seems like every single RAS-related stock is excelling except for us.
1 · Reply
beeelaaal
beeelaaal Feb. 3 at 6:40 AM
$VSTM SMA LINES converging !
0 · Reply
boston_drew
boston_drew Feb. 2 at 8:45 PM
$VSTM 19m+ sales coming out shortly
1 · Reply
Latest News on VSTM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 12, 2026, 4:01 PM EST - 22 days ago

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC

Dec 30, 2025, 3:37 PM EST - 5 weeks ago

Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC

Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Dec 29, 2025, 4:01 PM EST - 5 weeks ago

Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth

Dec 15, 2025, 4:01 PM EST - 7 weeks ago

Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth

Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference

Nov 25, 2025, 7:30 AM EST - 2 months ago

Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference

Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants

Nov 14, 2025, 12:41 AM EST - 2 months ago

Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants

Verastem Oncology Announces Proposed Public Offering of Common Stock

Nov 13, 2025, 4:07 PM EST - 2 months ago

Verastem Oncology Announces Proposed Public Offering of Common Stock

Verastem Oncology to Present at Upcoming Investor Conferences

Nov 5, 2025, 7:30 AM EST - 3 months ago

Verastem Oncology to Present at Upcoming Investor Conferences

Verastem, Inc. (VSTM) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 10:16 AM EST - 3 months ago

Verastem, Inc. (VSTM) Q3 2025 Earnings Call Transcript

Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

Nov 4, 2025, 7:30 AM EST - 3 months ago

Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors

Oct 23, 2025, 4:01 PM EDT - 3 months ago

Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors

Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025

Oct 23, 2025, 7:30 AM EDT - 3 months ago

Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma

Oct 19, 2025, 4:15 AM EDT - 3 months ago

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma

Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer

Aug 13, 2025, 4:29 PM EDT - 6 months ago

Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer

Verastem, Inc. (VSTM) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 8:55 PM EDT - 6 months ago

Verastem, Inc. (VSTM) Q2 2025 Earnings Call Transcript

Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

Aug 7, 2025, 4:05 PM EDT - 6 months ago

Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 29, 2025, 7:30 AM EDT - 6 months ago

Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer

Jul 24, 2025, 7:30 AM EDT - 6 months ago

Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer

Verastem: The Market Is Ignoring The Progress

Jul 16, 2025, 8:22 AM EDT - 7 months ago

Verastem: The Market Is Ignoring The Progress

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology

Jul 11, 2025, 4:12 PM EDT - 7 months ago

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology

Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer

Jun 30, 2025, 4:02 PM EDT - 7 months ago

Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer

Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers

Jun 26, 2025, 11:16 AM EDT - 7 months ago

Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

Jun 24, 2025, 4:02 PM EDT - 8 months ago

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

Jun 2, 2025, 9:40 AM EDT - 8 months ago

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

Verastem Oncology to Present at the Jefferies Global Healthcare Conference

May 28, 2025, 7:30 AM EDT - 8 months ago

Verastem Oncology to Present at the Jefferies Global Healthcare Conference

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma

May 22, 2025, 5:01 PM EDT - 9 months ago

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma

Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment

May 20, 2025, 8:30 AM EDT - 9 months ago

Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment

TEM

Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates

May 13, 2025, 4:34 PM EDT - 9 months ago

Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

May 8, 2025, 1:17 PM EDT - 9 months ago

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

U.S. FDA approves Verastem's cancer therapy

May 8, 2025, 12:23 PM EDT - 9 months ago

U.S. FDA approves Verastem's cancer therapy

Verastem Oncology Announces $75 million Private Placement

Apr 25, 2025, 9:00 AM EDT - 10 months ago

Verastem Oncology Announces $75 million Private Placement

Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors

Apr 23, 2025, 4:05 PM EDT - 10 months ago

Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors

Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination

Apr 10, 2025, 2:35 PM EDT - 10 months ago

Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination

Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025

Mar 25, 2025, 4:35 PM EDT - 11 months ago

Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025

Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

Mar 20, 2025, 4:01 PM EDT - 11 months ago

Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Feb 20, 2025, 4:05 PM EST - 1 year ago

Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference

Jan 29, 2025, 7:30 AM EST - 1 year ago

Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference

Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers

Jan 23, 2025, 7:30 AM EST - 1 year ago

Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers

Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

Jan 15, 2025, 7:30 AM EST - 1 year ago

Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China

Jan 14, 2025, 7:30 AM EST - 1 year ago

Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China

Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025

Jan 13, 2025, 7:30 AM EST - 1 year ago

Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025

Verastem: Planning The PDUFA Run-Up

Jan 3, 2025, 11:56 AM EST - 1 year ago

Verastem: Planning The PDUFA Run-Up

Verastem: BLA Acceptance Puts Key Goals In Sight

Jan 2, 2025, 11:39 AM EST - 1 year ago

Verastem: BLA Acceptance Puts Key Goals In Sight

Why Is Cancer-Focused Verastem Oncology Stock Trading Higher On Tuesday?

Dec 31, 2024, 10:59 AM EST - 1 year ago

Why Is Cancer-Focused Verastem Oncology Stock Trading Higher On Tuesday?

Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Dec 30, 2024, 4:30 PM EST - 1 year ago

Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Dec 18, 2024, 7:30 AM EST - 1 year ago

Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Verastem: Preparing For Upcoming Catalysts

Nov 27, 2024, 1:28 PM EST - 1 year ago

Verastem: Preparing For Upcoming Catalysts

Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference

Nov 26, 2024, 7:00 AM EST - 1 year ago

Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference

Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Nov 6, 2024, 4:05 PM EST - 1 year ago

Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Oct 31, 2024, 4:01 PM EDT - 1 year ago

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

CrozrX
CrozrX Feb. 4 at 2:53 AM
$VSTM First case where a tumor would rather get resected, than treated with VS-7375! Just hearing the name! 🤣 Joke aside, not easy situation having this dilemma! I'd say resectable first, then VS-7375/gemcitabine
0 · Reply
Geraldgenofranco1953
Geraldgenofranco1953 Feb. 4 at 1:03 AM
$SLS $IBRX $VSTM I do not know about others but Jack among few of the best traders I follow here in ST! I have been following him for years!
1 · Reply
jacksparo
jacksparo Feb. 4 at 12:26 AM
$SLS $IBRX $VSTM Shorting any cancer treatments stock in my personal opinion! Only my personal! Is really bad to the point I can feel the same disgusting feelings that I get when I heard about some criminal stealing the money that might help any person you love to live longer!!! RED LINE SERIOUS BLOCK!
2 · Reply
OneSmartBull
OneSmartBull Feb. 3 at 11:42 PM
$VSTM looks good
0 · Reply
idkmikes57
idkmikes57 Feb. 3 at 6:57 PM
$VSTM just looking back at this POS I owned still the same old.
0 · Reply
Fadoman
Fadoman Feb. 3 at 2:56 PM
$VSTM now volume has to show up I'm starting to think that only news will make it possible.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 3 at 2:18 PM
$VSTM RSI: 35.86, MACD: -0.5091 Vol: 0.52, MA20: 6.76, MA50: 8.19 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SagehenNed
SagehenNed Feb. 3 at 1:18 PM
$VSTM Check out ANL. Just raised $140 million and is surging pre-market. It now has a market cap greater than VSTM, all off a PR. Seems like every single RAS-related stock is excelling except for us.
1 · Reply
beeelaaal
beeelaaal Feb. 3 at 6:40 AM
$VSTM SMA LINES converging !
0 · Reply
boston_drew
boston_drew Feb. 2 at 8:45 PM
$VSTM 19m+ sales coming out shortly
1 · Reply
UWilDue0
UWilDue0 Feb. 2 at 8:07 PM
$VSTM I’m afraid to see how much lower this goes when market decides to pulls back. Any idea when we hear about wild type inclusion? Seems like a no brainer so will be extremely disappointed if they deny it
1 · Reply
sweddle
sweddle Feb. 2 at 7:50 PM
$VSTM
0 · Reply
SagehenNed
SagehenNed Feb. 2 at 7:39 PM
$VSTM XBI up 2% today and we're rolling over right on schedule.
0 · Reply
Universaal
Universaal Feb. 2 at 6:42 PM
$VSTM If you have money buy more stop fkn crying over and over it’s going higher
0 · Reply
boston_drew
boston_drew Feb. 2 at 5:48 PM
$VSTM I talked to the desk about Q4 results
2 · Reply
Drew613
Drew613 Feb. 2 at 5:25 PM
$VSTM Dan effect!!! He needs to find something else he’s good at lol! Still very
0 · Reply
Marketismanipulated2
Marketismanipulated2 Feb. 2 at 4:47 PM
$VSTM this clocksucker just won't run, will it?🤬🤬🤬
1 · Reply
sweddle
sweddle Feb. 2 at 3:56 PM
$VSTM
0 · Reply
PencilNeckGeek
PencilNeckGeek Feb. 2 at 3:32 PM
$VSTM Fucking turd can't even break and hold $6.10
0 · Reply
SagehenNed
SagehenNed Feb. 2 at 3:21 PM
$VSTM Biotechs are ripping this morning and we can't get out of our own way.
1 · Reply
Nodaz
Nodaz Feb. 2 at 8:44 AM
$VSTM will they report 2025 FR end February, begin March or on or after March 19?
0 · Reply
Marketismanipulated2
Marketismanipulated2 Feb. 2 at 4:41 AM
$VSTM This better reverse soon and WHERE IN THE FUCK is that useless CEO?
0 · Reply